May 28, 2025 / 08:00AM GMT
Operator
Greetings and welcome to the Nykode Therapeutics Q1 2025 financial results presentation. At this time, all participants are your listen-only mode.
(Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Michael Engsig, CEO of Nykode Therapeutics. Please go ahead, Michael.
Michael Engsig - Nykode Therapeutics ASA - Chief Executive Officer
Thank you very much, Kevin. And, also from my side, a very warm welcome to all participants to this webcast for our first quarter results and updates from the business.
A quick reminder of our forward-looking statements, assuming you're all familiar with this kind of statements, we will move on.
As usual, I am very happy to have with me here today Agnete Fredriksen, our Chief Scientific Officer and Business Development and Co-founder; as well as Harald Gurvin, our Chief Financial Officer, and together we'll try to take you through a deep dive in the business update and the financial numbers for the first quarter.
So, happy to
Q1 2025 Nykode Therapeutics ASA Earnings Call Transcript
May 28, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers